Invasive Aspergillosis Clinical Trial
Official title:
F901318 - A Phase I, Single Intravenous Dose, Safety, Tolerability and Pharmacokinetics Study in Healthy Male and Female Subjects
Open label evaluation of a single intravenous dose of F901318 to healthy male and female subjects with pharmacokinetic and safety and tolerability evaluation.
Open label single intravenous dose, single group study. Eight subjects (ideally 4 male and 4
female, minimum of two females) will be studied. The drug product will be a F901318 solution
for infusion (6mg/mL). The dose will be 4 mg/kg delivered in the fasted state (8 hours
minimum) by intravenous infusion over 2 hours. Each subject will be on study for
approximately 6 weeks. Each subject will reside at the Clinical Research Unit (CRU) from Day
-1 (the day before dosing) to Day 4 (72 hours post-dose). Blood samples for pharmacokinetic
evaluation will be obtained up to and including 120 hours post dose. Safety and tolerability
will also be assessed.
Subjects will return to the clinical unit at 96 and 120 hours for pharmacokinetic blood
sampling.
All subjects will return for a post-study visit 8 to 10 days after the dose of study
medication.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06028451 -
ManagemEnt of Antifungal Drug in Invasive Aspergillosis：a Real-word Study
|
||
| Completed |
NCT00163722 -
A Multicentre Randomised Controlled Trial Comparing Two Strategies for the Diagnosis of Invasive Aspergillosis in High-risk Haematology Patients
|
Phase 3 | |
| Completed |
NCT02394483 -
Single Ascending Oral Dose Study of F901318
|
Phase 1 | |
| Completed |
NCT01128907 -
Galactomannan Antigen in Bronchoalveolar Lavage in the Diagnosis of Invasive Aspergillosis in Neutropenic Patients
|
N/A | |
| Completed |
NCT00404092 -
Caspofungin Maximum Tolerated Dose in Patients With Invasive Aspergillosis
|
Phase 2 | |
| Recruiting |
NCT01386437 -
Natural History of Individuals With Immune System Problems That Lead to Fungal Infections
|
||
| Withdrawn |
NCT02912026 -
Radiolabelled IV and Oral Metabolism Study of F901318
|
Phase 1 | |
| Withdrawn |
NCT03095547 -
Drug/Drug Interactions With F901318
|
Phase 1 | |
| Completed |
NCT02737371 -
Multiple Ascending Oral Dose Study of F901318 in Healthy Subjects
|
Phase 1 | |
| Terminated |
NCT00836875 -
A Study To Evaluate The Safety Of Voriconazole As Treatment Of Invasive Aspergillosis (Fungal Infection) And Other Rare Molds In Children
|
Phase 3 | |
| Active, not recruiting |
NCT00838643 -
Invasive Aspergillosis After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
|
N/A | |
| Terminated |
NCT04876716 -
Azole-echinocandin Combination Therapy for Invasive Aspergillosis
|
Phase 3 | |
| Recruiting |
NCT05101187 -
Olorofim Aspergillus Infection Study
|
Phase 3 | |
| Enrolling by invitation |
NCT02104479 -
Diagnostic Accuracy of Pleural Effusion Aspergillosis Biomarker Testing
|
||
| Not yet recruiting |
NCT05707832 -
A Study of ABCD for Injection in Subjects With Invasive Candidiasis and Invasive Aspergillus
|
Phase 3 | |
| Recruiting |
NCT06382922 -
Role of Antifungal Prophylaxis in Elderly Patients With Acute Myeloid Leukemia During Consolidation Therapy
|
||
| Terminated |
NCT02396225 -
Concentrations of Voriconazole in Blood and BAL-fluid After Inhalation and Oral Administration
|
N/A | |
| Recruiting |
NCT00843804 -
Surveillance for Nosocomial Infections in Pediatric Cancer Patients
|
N/A | |
| Completed |
NCT00334412 -
COMBISTRAT: AmBisome® in Combination With Caspofungin for the Treatment of Invasive Aspergillosis
|
Phase 4 | |
| Completed |
NCT04550936 -
Patterns of Real-World Isavuconazole Use - a Study of Patients With Mucormycosis or Invasive Aspergillosis
|